Experimental human muscle pain induced by intramuscular injections of bradykinin, serotonin, and substance P

European Journal of Pain

Volumn 3, Issue 2, 1999, Pages 93-102

  Babenko, Victor ^a   Graven Nielsen, Thomas ^a   Svensson, Peter ^a,b   Drewes, Asbjørn M ^a,c   Jensen, Troels Staehelin ^b   Arendt Nielsen, Lars ^a  

^a AALBORG UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Algogenic substances; Muscle pain; Muscular hyperalgesia

Indexed keywords

BRADYKININ; SEROTONIN; SUBSTANCE P;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN EXPERIMENT; MALE; MYALGIA; PAIN THRESHOLD; PRIORITY JOURNAL;

EID: 0033067790     PISSN: 10903801     EISSN: None     Source Type: Journal    
DOI: 10.1053/eujp.1998.0103     Document Type: Article

References (49)

1. Arendt-Nielsen L., Graven-Nielsen T., Drewes A. M. Referred pain and hyperalgesia related to muscle and visceral pain. IASP Newsletter. January/February: 1998.
2. Armstrong D. Bradykinin, kallidin and kallikrein. Section B: Pain. Erdos E. Handbook of experimental pharmacology. 1970;434-473 Springer-Verlag Berlin, Heidelberg.
3. Armstrong D., Dry R. M. L., Keele C. A., Markham J. W. Observations on chemical excitant of cutaneous pain in man. J Physiol. 120: 1953;26-351.
4. Bonica J. J. History of pain concepts and therapies. Bonica J. J. The Management of Pain. 1990;3-17 Lea & Febiger, Philadelphia.
5. Brimijoin S., Lundberg J. M., Brodin E., Hokfelt T., Nilsson G. Axonal transport of substance P in the vagus and sciatic nerves of the guinea pig. Brain Res. 191: 1980;43-457.
6. Coffman J. D. The effect of aspirin on pain and hand blood flow responses to intra-arterial injection of bradykinin in man. Clin Pharmacol Ther. 7: 1966;6-37.
7. Di Rosa M., Giroud J. P., Willoughby D. A. Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. J Pathol. 104: 1971;5-29.
8. Dragovic T., Minshall R., Jarkman H. L., Wang L. X., Erdos E. G. Kininase II-type enzymes. Their putative role in muscle energy metabolism. Diabetes. 45:1996;34-37.
9. Dray A., Patel I. A., Perkins M. N., Rueff A., Urban L. Desensitization of bradykinin-induced activation of peripheral nociceptors. Agents Actions Suppl. 38: 1992;3-97.
10. Dray A. Inflammatory mediators of pain. Br J Anaesth. 75: 1995;25-131.
11. Drewes A. M., Helweg-Larsen S., Petersen P., Brennum J., Andreasen A., Poulsen L. H., Jensen T. S. McGill Pain Questionnaire translated into Danish: experimental and clinical findings. Clin J Pain. 9: 1993;0-87.
12. Dubner R. Pain and hyperalgesia following tissue injury: new mechanism and new treatments. Pain. 44: 1991;13-214.
13. Dubner R., Ren K. Central mechanisms of thermal and mechanical hyperalgesia following tissue inflammation. Boivie J., Hansson P., Lindblom U. Touch, Temperature, and Pain in Health and Disease: Mechanisms and Assessment, Progress in Pain Research and Management. 1994;267-277 IASP Press, Seattle.
14. Fock S., Mense S. Excitatory effects of 5-hydroxytryptamine, histamine and potassium ions on muscular group IV afferent units: a comparison with bradykinin. Brain Res. 105: 1976;59-469.
15. Graven-Nielsen T., Fenger-Grøn L. S., Svensson P., Steengaard-Pedersen K., Arendt-Nielsen L., Jensen T. S. Quantification of deep and superficial sensibility in saline-induced muscle pain - a psychophysical study. Somatosens Motor Res. 15: 1998;6-53.
16. Handwerker H. O. Influence of algogenic substances and prostaglandin on the discharge of unmyelinated cutaneous nerve fibers identified as nociceptors. Bonica J. J. Advances in Pain Research and Therapy. 1976;41-45 Raven Press, New York.
17. Handwerker H. O., Reeh P. W. Pain and inflammation. Bond M. R., Charlton J. E., Woolf C. J. Proceedings of the VIth World Congress on Pain. Pain Research and Clinical Management. 1991;59 Elsevier, Amsterdam.
18. Hargreaves K. M., Costello A. Glucocorticoids suppress levels of immunoreactive bradykinin in inflamed tissue as evaluated by microdialysis probes. Clin Pharmacol Ther. 48: 1990;68-178.
19. Hartung H. P., Wolters K., Toyka K. V. Substance P: binding properties and studies on cellular responses in guinea pig macrophages. J Immunol. 136: 1986;856-3863.
20. Herbert M. K., Schmidt R. F. Activation of normal and inflamed fine articular afferent units by serotonin. Pain. 50: 1992;9-88.
21. Hoheisel U., Mense S. Long-term changes in discharge behaviour of cat dorsal horn neurones following noxious stimulation of deep tissues. Pain. 36: 1989;39-247.
22. Iggo A. Non-myelinated afferent fibres from mammalian skeletal muscle. J Physiol. 155: 1961;2-53.
23. Jensen K., Tuxen C., Pedersen-Bjergaard U., Jansen I., Edvinsson L., Olesen J. Pain and tenderness in human temporal muscle induced by bradykinin and 5-hydroxytraptamine. Peptides. 11: 1990;127-1132.
24. Jensen K., Tuxen C., Pedersen-Bjergaard U., Jansen I. Pain, tenderness, wheal and flare induced by substance-P, bradykinin and 5-hydroxytryptamine in humans. Cephalalgia. 11: 1991;75-182.
25. Kantor G., Jarvik M. E., Wolff B. B. Bradykinin as a mediator of human pain. Proc Soc Exp Biol Med. 126: 1967;05-507.
26. Kosek E., Ekholm J., Hansson P. Increased pressure pain sensibility in fibromyalgia patients is located deep to the skin but not restricted to muscle tissue. Pain. 63: 1995;35-339.
27. Kumazawa T., Mizumura T., Minagawa M., Tsujii Y. Sensitizing effects of bradykinin on the heat responses of the visceral nociceptor. J Neurophysiol. 66: 1991;819-1824.
28. Lembeck F., Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol. 310: 1979;75-183.
29. Lembeck F., Popper H., Juan H. Release of prostaglandins and the mechanisms of analgesia produced by aspirin-like drugs. Br J Pharmacol. 49: 1976;6-97.
30. Levine J. D., Taiwo Y. O., Collins S. D., Tam J. K. Noradrenaline hyperalgesia is mediated through interaction with sympathetic postganglionic neurone terminals rather than activation of primary afferent nociceptors. Nature. 323: 1986;58-160.
31. Levine J. D., Fields H. L., Basbaum A. I. Peptides and the primary afferent nociceptor. J Neurosci. 13: 1993;273-2286.
32. Lim R. K., Miller D. G., Guzman F., Rodgers D. W., Rogers R. W., Wang S. K., Chao P. Y., Shih T. Y. Pain and analgesia evaluated by the intraperitoneal bradykinin-evoked pain method in man. Clin Pharmacol Ther. 8: 1967;21-542.
33. Löfstrom B., Pernow B., Wanren J. Vasodilating action of substance P in the human forearm. Acta Physiologica Scandinavica. 63: 1965;11-324.
34. Manning D. C., Raja S. N., Meyer R. A., Campbell J. N. Pain and hyperalgesia after intradermal injection of bradykinin in humans. Clin Pharmacol Ther. 50: 1991;21-729.
35. Mense S. Nervous outflow from skeletal muscle following chemical noxious stimulation. J Physiol. 267: 1977;5-88.
36. 2. Brain Res. 225: 1981;5-105.
37. Mense S. Nociception from skeletal muscle in relation to clinical muscle pain. Pain. 54: 1993;41-289.
38. Mense S., Meyer H. Bradykinin-induced modulation of the response behaviour of different types of feline group III and IV muscle receptors. J Physiol. 398: 1988;9-63.
39. Mense S., Schmidt R. F. Activation of group IV afferent units from muscle by algesic agents. Brain Res. 72: 1976;05-310.
40. Moskowitz M. A., Brody M., Liu-Chen L. Y. In vitro release of immunoreactive substance P from putative afferent nerve endings in bovine pia arachnoid. Neuroscience. 9: 1983;09-814.
41. Paintal A. S. Functional analysis of group III afferent fibres of mammalian muscle. J Physiol. 152: 1960;50-270.
42. 3receptors. Trends Neurosci. 9: 1986;24-428.
43. Sicuteri F., Fanciulacci M., Franchi G., Del Bianco P. L. Serotonin-bradykinin potentiation on the pain receptors in man. Life Sci. 4: 1965;09-316.
44. Simone D. A., Marchettini P., Caputi G., Ochoa J. L. Identification of muscle afferents subserving sensation of deep pain in humans. J Neurophysiol. 72: 1994;83-889.
45. Svensson P., Arendt-Nielsen L., Nielsen H., Larsen J. K. Effect of chronic and experimental jaw muscle pain on pain-pressure thresholds and stimulus-response curves. J Orofac Pain. 9: 1995;47-356.
46. Taiwo Y. O., Levine J. D. Characterization of the arachidonic metabolites mediating bradykinin and noradrenaline hyperalgesia. Brain Res. 458: 1988;02-406.
47. Vecchiet L., Dragani L., De Bigontina P., Obletter G., Giamberardino M. A., Vecchiet L., Albe-Fessard D., Lindblom U., Giamberardino M. Experimental referred pain and hyperalgesia from muscles in humans. New Trends in Referred Pain and Hyperalgesia. 1993;Elsevier Science publishers B. V. Amsterdam. p. 239-249.
48. Whalley E. T., Clegg S., Steward J. M., Vavrek R. J. Antagonism of the analgesic action of bradykinin on the human blister base. Adv Exp Med Biol. 247 A: 1989;61-268.
49. White D. M., Helme R. D. Release of substance P from peripheral nerve terminals following electrical stimulation of the sciatic nerve. Brain Res. 336: 1985;7-31.